STOCK TITAN

ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROKIDNEY CORP. reported that Chief Technical Officer Kenneth Thomas Locke received an employee stock option grant covering 750,000 shares of Class A Common Stock. The options have an exercise price of $1.8900 per share and expire on July 1, 2036.

The award is compensation-related rather than an open-market purchase. According to the vesting terms, 25% of the option vests on the first anniversary of July 1, 2026, with the remaining 75% vesting in substantially equal monthly installments over the following 36 months, subject to continued employment. Following this grant, Locke holds 750,000 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Locke Kenneth Thomas
Role Chief Technical Officer
Type Security Shares Price Value
Grant/Award Employee stock option (right to buy) 750,000 $0.00 --
Holdings After Transaction: Employee stock option (right to buy) — 750,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 750,000 options Employee stock option grant to CTO on July 1, 2026
Exercise price $1.8900 per share Strike price for employee stock options
Underlying shares 750,000 shares Class A Common Stock underlying the options
Expiration date July 1, 2036 Option expiration for CTO grant
Post-transaction derivative holdings 750,000 options Total derivative securities held directly after grant
Initial vesting portion 25% of grant Vests on first anniversary of July 1, 2026
Remaining vesting period 36 months Monthly vesting of remaining 75% after first anniversary
Employee stock option financial
"Employee stock option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: "1.8900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests 25% on 1st anniversary of July 1, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-07-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did PROKIDNEY CORP. (PROK) disclose about Kenneth Locke in this Form 4?

The filing shows Chief Technical Officer Kenneth Thomas Locke received a grant of 750,000 employee stock options. These options are compensation-related awards, not open-market purchases, and give him the right to buy Class A Common Stock at a fixed exercise price if they vest.

How many stock options did PROKIDNEY CORP. (PROK) grant to its CTO?

Kenneth Thomas Locke was granted 750,000 employee stock options. Each option relates to one share of Class A Common Stock, giving him the right to buy up to 750,000 shares if he exercises the options after they vest and before expiration.

What is the exercise price and expiration date of the PROK CTO’s options?

The options have an exercise price of $1.8900 per share and expire on July 1, 2036. This means Locke can purchase Class A Common Stock at $1.8900 per share, once vested, any time before the July 1, 2036 expiration date.

How do the PROK CTO stock options vest over time?

Vesting occurs 25% on the first anniversary of July 1, 2026, with the remaining 75% vesting in substantially equal monthly installments over 36 months. Vesting is conditioned on Kenneth Thomas Locke’s continued employment with ProKidney during the vesting period.

Is this PROK Form 4 transaction a stock purchase or a compensation grant?

The transaction is a compensation grant, coded as a grant, award, or other acquisition. It represents an employee stock option award rather than an open-market stock purchase, so no cash outlay by Kenneth Thomas Locke occurred at the time of grant.

What are Kenneth Locke’s derivative holdings after this PROK option grant?

After the transaction, Kenneth Thomas Locke holds 750,000 derivative securities directly. These consist of the newly granted employee stock options tied to Class A Common Stock, as reported in the Form 4’s total shares following the transaction field.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Locke Kenneth Thomas

(Last)(First)(Middle)
2000 FRONTIS PLAZA BLVD
SUITE 250

(Street)
WINSTON-SALEM NORTH CAROLINA 27103

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee stock option (right to buy)$1.8907/01/2026A750,000 (1)07/01/2036Class A Common Stock750,000$0750,000D
Explanation of Responses:
1. The option vests 25% on 1st anniversary of July 1, 2026 and the remaining 75% vests in substantially equal monthly installments for 36 months thereafter, subject to continued employment.
/s/ Todd Girolamo, attorney in fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)